查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1440104

藥用管瓶和安瓿：市場佔有率分析、行業趨勢和統計、成長預測（2024-2029）

Pharmaceutical Glass Vials And Ampoules - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)
出版日期: | 出版商: Mordor Intelligence | 英文 154 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

藥用玻璃管瓶和安瓿市場規模預計到 2024 年為 148.2 億美元，在預測期內（2024-2029 年）預計到 2029 年將達到 207.3 億美元，年複合成長率為 6.94%。

藥用玻璃瓶和安瓿 - 市場

多年來，玻璃一直是藥品包裝行業安全包裝的首選材料，是維持各種化學成分的理想選擇。玻璃管瓶和安瓿的透明度也更高，更容易檢查和監控其內容物。

主要亮點

  • 不斷成長的製藥業推動市場成長。人口稠密的國家對藥用管瓶和安瓿的需求正在增加。這些國家藥品產量的增加進一步增加了需求。此外，印度和中國等新興國家醫療保健支出的增加是市場成長的另一個驅動力。
  • 由於有利的人口結構、低廉的人事費用和豐富的資源，新興市場被描述為成長和繁榮的國家。金磚國家（巴西、俄羅斯、印度、中國和南非）是頂級新興經濟體。對下游經濟體進行分類有幾種不同的方法。 MIST 國家包括墨西哥、印尼、韓國和土耳其。另一種解釋將這兩個群體分為果子狸（哥倫比亞、印尼、越南、埃及、土耳其和南非）和孟加拉、埃及、印尼、伊朗、韓國、墨西哥、奈及利亞、巴基斯坦、菲律賓、土耳其和越南。
  • 玻璃的顯著獨特優勢，例如化學耐久性和維持各種化學成分的適用性，是包裝供應商選擇玻璃作為製藥材料的因素。此外，玻璃管瓶和安瓿瓶的透明度更高，更容易觀察和監控內容物。這提供了進一步的保護，因為玻璃對大多數藥物具有化學耐受性，並且相對不滲透空氣和濕氣。
  • 傳統上，鋁和玻璃一直是整個藥品包裝的首選材料。隨著時間的推移，這些材料由於原料價格和其他因素而變得昂貴，並且不再為大眾消費的包裝產品提供經濟可行的解決方案。這引入了塑膠作為一種選擇。
  • COVID-19感染疾病在世界各地對管瓶和安瓿產生了巨大的需求。全球不同國家冠狀病毒疫苗的大規模生產正在對市場格局產生重大影響。受疫情影響，研發創新經歷了進步的黃金時期，藥物輸送和包裝市場也經歷了持續的成長和創新。無論管瓶、瓶子、安瓿、自動注射器、連網型設備，還是拯救生命的 COVID-19感染疾病的低溫運輸儲存，藥品包裝和分銷行業正在改變整個大流行整體的藥品交付方式，發揮著重要作用。在。
  • 此外，企業在開發有效疫苗方面活動的增加以及疫苗核准的增加也促進了該行業的成長。 2022年8月，美國FDA批准了Moderna COVID - 19感染疾病和輝瑞-BioNTech感染疾病作為首個疫苗，核准作為疫苗的二價製劑，在接種疫苗或加強接種後至少2個月內用作單次加強注射。因此， 感染疾病-19 後疫苗行業的持續發展增加了對管瓶和安瓿的需求。

藥用管瓶和安瓿的市場趨勢

疫苗佔據主要市場佔有率

  • 疫苗需求的不斷成長，加上慢性病盛行率的上升，推動了藥品包裝產業的整體成長。因此，管瓶和安瓿市場預計將大幅成長。
  • 疫苗包裝解決方案的需求激增是由於向消費者提供大量疫苗以及世界衛生組織和聯合國兒童基金會等主流組織組織的大規模疫苗接種活動。這導致醫院、診斷中心、調查計畫和其他醫療保健部門等最終用途部門對玻璃安瓿和管瓶的需求顯著增加。
  • 此外，由於多種因素，包括持續努力對抗感染疾病、新出現的流行病以及人們對疫苗接種重要性的認知不斷增強，全球對疫苗的需求正在穩步成長。
  • 整個製造過程中的技術轉移和合作夥伴關係將極大地影響供應彈性和擴充性，特別是在 COVID-19感染疾病的開發過程中。許多製造商依賴從其他製造商接收散裝疫苗，將其裝入管瓶、安瓿和包裝中進行分發。
  • 對藥品包裝（尤其是疫苗）的嚴格監管要求通常傾向於使用玻璃，因為玻璃具有化學惰性且能夠承受滅菌過程。這種合規性增加了藥品包裝中對管瓶和安瓿的需求。確保充足的藥用管瓶供應以在全球範圍內分發疫苗對於全球應對措施的成功至關重要。世界各國政府和製藥公司已下達數億份訂單，促使初級包裝玻璃製造商提高產能。
  • 這些努力在許多國家取得了成功，使政府能夠獲得和管理疫苗。例如，截至 2023 年 11 月，印度政府已接種了超過 22 億例 COVID-19 疫苗。根據 CNN 和 OWID 報導，截至 2023 年 3 月 20 日，全球已接種約 130 億劑 COVID-19感染疾病，其中美國約 6.72 億劑。

亞太地區預計將出現顯著成長

  • 隨著中國建立了製藥業的標準框架，中國的藥用玻璃安瓿和管瓶市場預計將擴大。國家越來越注重藥品包裝材料在藥品儲存過程中的穩定性以及包裝在使用過程中的安全性。由於其耐用性、非反應性、透明性、環境友善性和多功能性，製藥公司擴大使用玻璃包裝。此外，醫療保健系統投資和研發的增加以及藥品支出的增加正在推動對管瓶的需求。
  • 日本的製藥工業是世界上成長最快的工業之一，僅次於美國。這是由於該國繼續專注於開發學名藥藥和取得專利的藥物和疫苗，以及政府對希望在該國投資的國際公司採取放鬆管制的措施。
  • 隨著印度製藥業的成長，印度對玻璃包裝的需求預計將增加。為了幫助藥品製造商應對日益複雜的產能和品質挑戰，同時滿足印度市場對基本藥物的需求，因為行業相關人員專注於利用市場成長。我們在 開設了一家玻璃管工廠。
  • 例如，2023年7月，美國科技公司康寧與法國藥用玻璃製造商SGD Pharma成立的合資企業將在印度特倫甘納邦建造藥用玻璃管工廠，以擴大印度的藥品生產。新廠將匯集康寧專有的玻璃塗層技術平台 Velocity Vial 和 SGD Pharma 的管瓶轉換專業知識，以提高管瓶和填充線的生產率，並加快全球注射劑的交付。新工廠的奠基儀式將於2023年6月舉行，該公司預計將在該工廠投資約50億盧比（6,030萬美元），預計將創造約150個就業機會。 SGD Pharma 的 Vemula 工廠預計將於 2024 年開始生產 Velocity 西林瓶，預計 2025 年開始生產藥管。
  • 注射劑的需求量很大，因為它們避免了困擾口服營養素的許多問題。隨著醫療保健需求的增加，對藥物、疫苗和其他包裝在管瓶和安瓿中的醫療產品的需求也在增加，這給此類藥物的生產帶來了壓力。這將迫使製藥公司轉向契約製造。例如，創新軟體、生命科學和深度科技公司開發商 Bridgewest Group 於 2023 年 5 月推出了一個新的合約開發和製造組織 (CDMO)，專注於無菌注射藥品。 CMDO 位於西澳大利亞州，由 NovaCina 營運。

藥用管瓶和安瓿產業概述

藥用管瓶和安瓿市場高度分散，主要參與者包括 Schott AG、Gerresheimer AG、Stevanato Group、Nipro Corporation 和 Kapoor Glass India Pvt. Ltd。市場參與者正在採取合作夥伴關係和收購等策略來增強其產品供應並獲得永續的競爭優勢。

  • 2023 年 10 月 - Gerresheimer 推出含有 COP（環烯烴聚合物）的管瓶，這是適合敏感生物來源產品填充和儲存的解決方案。 COP管瓶非常適合在低溫和低溫環境下使用 mRNA 活性成分。 Gerresheimer 使用結合了玻璃和塑膠最佳性能的高品質聚合物，擴大了各種品質的 RTF管瓶系列。
  • 2023 年 2 月 - NOVA Ompi 簽署預售協議，以估計價格 1600 萬歐元（1691 萬美元）購買位於拉丁（義大利）靠近斯蒂瓦那托集團其他資產的棕地地。維修的棕地工廠將生產 EZ 填充注射器、管瓶和其他產品。

其他福利

  • Excel 格式的市場預測 (ME) 表
  • 3 個月分析師支持

目錄

第1章 簡介

  • 研究假設和市場定義
  • 調查範圍

第2章調查方法

第3章執行摘要

第4章市場洞察

  • 市場概況
  • 產業吸引力－波特五力分析
    • 供應商的議價能力
    • 買方議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵意強度
  • 評估 COVID-19 對產業的影響
  • 產業價值鏈分析

第5章市場動態

  • 市場促進因素
    • 新興國家製藥業的成長
    • 可回收性提高了玻璃的產品價值
  • 市場限制因素
    • 提高替代來源的相關性

第6章市場區隔

  • 按用途
    • 疫苗
    • 其他（胰島素、生物製藥、其他）
  • 按地區
    • 北美洲
      • 美國
      • 加拿大
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 義大利
      • 西班牙
      • 其他歐洲國家
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 韓國
      • 其他亞太地區
    • 世界其他地區

第7章 競爭形勢

  • 公司簡介
    • Schott AG
    • Gerresheimer AG
    • Stevanato Group SPA
    • NIPRO Corporation
    • Kapoor Glass India Pvt. Ltd
    • SGD SA（SGD Pharma）
    • AAPL Solutions Pvt. Ltd
    • CORNING INCORPORATED
    • BOROSIL
    • Stoelzle Oberglas GmbH
    • Accu-Glass LLC
    • Adit Containers Private Limited
    • Agrado SA
    • Birgimefar Group
    • J. Penner Corporation
    • BORMIOLI PHARMA SPA
    • SISECAM

第8章投資分析

第9章市場的未來

簡介目錄
Product Code: 69988

The Pharmaceutical Glass Vials And Ampoules Market size is estimated at USD 14.82 billion in 2024, and is expected to reach USD 20.73 billion by 2029, growing at a CAGR of 6.94% during the forecast period (2024-2029).

Pharmaceutical Glass Vials And Ampoules - Market

Glass has long been the go-to material for safe packaging in the pharmaceutical packaging industry and is best suited to sustaining various chemical compositions. Also, glass vials and ampoules provide enhanced transparency, which allows easy inspection and monitoring of their contents.

Key Highlights

  • The growing pharmaceutical industry aids the market's growth. The demand for pharmaceutical glass vials and ampoules arises in densely populated countries. The increasing pharmaceutical production in these countries is further increasing demand. In addition, growing healthcare spending in developing countries like India and China is another driver of the market's growth.
  • Emerging markets are described as growing and prosperous nations owing to their favorable demographic conditions, low labor costs, and abundant resources. The BRICS nations (Brazil, Russia, India, China, and South Africa) are the top developing economies. There are a few different approaches to classifying lower-tier economies. MIST countries include Mexico, Indonesia, South Korea, and Turkey. Another interpretation separates the two groups into CIVETS (Colombia, Indonesia, Vietnam, Egypt, Turkey, and South Africa) and Bangladesh, Egypt, Indonesia, Iran, Korea, Mexico, Nigeria, Pakistan, the Philippines, Turkey, and Vietnam.
  • The significant characteristic benefits of glass, such as chemical durability and suitability to sustain various chemical compositions, are some factors driving packaging vendors to choose glass as a pharmaceutical material. Additionally, glass vials and ampoules offer improved transparency, making viewing and monitoring the contents easier. This provides additional protection because glass is chemically resistant to most pharmaceuticals and comparatively impermeable to air and moisture.
  • Traditionally, the preferred materials across pharmaceutical packaging have been aluminum and glass. Over time, these materials became expensive due to raw material prices and other factors and could not provide economically viable solutions for packaging products across mass consumption. That marked the advent of plastics as an option.
  • The COVID-19 pandemic caused massive demand for vials and ampoules worldwide. The large-scale production of the Coronavirus vaccine in various countries worldwide has significantly affected the market scenario. As a result of the pandemic, R&D innovation has experienced a golden period of advancement, and the drug delivery and packaging markets have also experienced continuous growth and innovation. Whether vials, bottles, ampoules, auto-injectors, connected devices, or cold chain storage of lifesaving COVID-19 vaccines, the pharmaceutical packaging and delivery sectors have played a critical role in the pandemic in transforming the way of delivering medicines in general.
  • Further, increasing company activities in developing effective vaccines and growing vaccine approvals are also contributing to the segment's growth. In August 2022, the US FDA approved the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine as bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination. Therefore, these continued developments in the vaccine industry post-COVID-19 have bolstered the demand for glass vials and ampoules.

Pharmaceutical Glass Vials and Ampoules Market Trends

Vaccines to Hold Significant Market Share

  • The increasing demand for vaccines, coupled with the rising prevalence of chronic diseases, contributes to the overall growth of the pharmaceutical packaging industry. The market for glass vials and ampoules is expected to witness a substantial increase as a result.
  • The surge in demand for vaccine packaging solutions is aided by the high number of vaccines acquired by consumers and the major vaccination drives organized by mainstream organizations like WHO and UNICEF. This has led to a significant increase in demand for glass ampoules and vials in end-use sectors such as hospitals, diagnostic centers, research programs, and other healthcare units.
  • Furthermore, the global demand for vaccines has been steadily increasing due to various factors, including ongoing efforts to combat infectious diseases, emerging pandemics, and a growing awareness of the importance of vaccination.
  • The flexibility and scalability of supply are greatly impacted by technology transfers and partnerships throughout the manufacturing process, particularly with the development of COVID-19 vaccines. Many manufacturers rely on receiving bulk vaccines from another manufacturer that they then fill into vials, ampoules, and packages for distribution.
  • Stringent regulatory requirements for pharmaceutical packaging, especially for vaccines, often favor using glass due to its chemical inertness and the ability to withstand sterilization processes. This compliance drives the demand for glass vials and ampoules in pharmaceutical packaging. Ensuring an adequate supply of pharmaceutical glass vials for the distribution of the vaccine worldwide is crucial for the success of a global response. Governments and pharmaceutical companies worldwide are placing hundreds of millions of orders and urging primary packaging glass manufacturers to increase their production capacity.
  • These initiatives proved successful in many countries, acquiring and administrating vaccines by their respective governments. For example, as of November 2023, the Indian government had administered more than 2.2 billion COVID-19 vaccinations. According to CNN and OWID, as of March 20, 2023, about 13 billion COVID-19 vaccine doses had been administered globally, with the United States accounting for almost 672 million.

Asia Pacific Expected to Witness Major Growth

  • The Chinese pharmaceutical glass ampoules and vials market is expected to expand as China has established a standard framework for the pharmaceutical industry. The country is increasingly focusing on the stability of pharmaceutical packaging materials during drug storage and the safety of the packaging when used. Pharmaceutical companies increasingly use glass packaging because of its durability, non-reactivity, transparency, eco-friendliness, and versatility. Additionally, glass vials are in high demand due to increasing investment and R&D in healthcare systems and rising drug spending.
  • Japan's pharmaceutical industry is one of the fastest growing in the world, second only to the United States. This is due to the country's continued focus on developing generic and patented drugs and vaccines and the government's deregulatory measures for international companies wishing to invest in the country. In May 2023, Nipro Corporation Japan, one of the world's largest companies, presented its investment of over PGK 100 million (USD 26.48 million) at the Sesvete plant, where it is constructing a new ampoules and vial factory (Pharmaceuticals) Nippro Pharma Packaging (Hrvatska) for the pharmaceutical industry. Nippro Corporation Japan purchased the old Piramida factory (Sesvete) from the Blue Sea Capital fund (which was recently named the year's most successful acquisition).
  • The demand for glass packaging in India is expected to increase as the Indian pharmaceutical industry grows. Players in the industry are focusing on capitalizing on market growth, so they are opening glass tubing facilities to help the companies support drug manufacturers in addressing progressively complex capacity and quality challenges while fulfilling the need for essential medicines in the Indian market.
  • For instance, in July 2023, a joint venture between United States technology company Corning and French pharmaceutical glassmaker SGD Pharma will build a pharmaceutical glass tubing facility in the Indian state of Telangana to scale up pharmaceutical manufacturing in India. The new facility will bring together Corning's proprietary glass coating technology platform, Velocity Vial, and SGD Pharma's vial converting expertise to enhance vial and fill-line productivity and the delivery speed for injectable treatments worldwide. The groundbreaking ceremony for the new facility was held in June 2023, and the company expects to invest approximately INR 5 billion (USD 60.3 million) in the facility, which is expected to create about 150 jobs. The manufacturing of Velocity Vials is expected to start at SGD Pharma's Vemula facility in 2024, with the production of pharmaceutical tubing expected to begin in 2025.
  • The demand for injectables is increasing as they can bypass many issues plaguing orally administered nutrients. As healthcare needs increase, the demand for pharmaceuticals, vaccines, and other medical products packaged in vials and ampoules will also increase, creating pressure on the production of such medicines. This leads to pharmaceutical companies switching to contract manufacturers. For instance, in May 2023, Bridgewest Group, a company developing innovative software, life sciences, and deep tech companies, launched a new contract development and manufacturing organization (CDMO) focusing on sterile injectable drug products. The CMDO is located in Western Australia and will operate under NovaCina.

Pharmaceutical Glass Vials and Ampoules Industry Overview

The pharmaceutical glass vials and ampoules market is highly fragmented, with the presence of major players like Schott AG, Gerresheimer AG, Stevanato Group, Nipro Corporation, and Kapoor Glass India Pvt. Ltd. Players in the market are adopting strategies such as partnerships and acquisitions to enhance their product offerings and gain sustainable competitive advantage.

  • October 2023 - Gerresheimer has launched vials containing COP (Cyclic Olefin Polymer), a suitable solution for filling and storing susceptible biological products. COP vials are ideal for using mRNA-active ingredients in cold and cryogenic environments. Gerresheimer is broadening its range of RTF glass vials, which are available in various qualities, with a high-quality polymer that combines the best properties of both glass and plastic.
  • February 2023 - NOVA Ompi entered into a pre-sale agreement to purchase a brownfield site in Latin (Italy), close to other facilities of the Stevanato group, for an approximate price of EUR 16,0 million (USD 16.91 million). After renovation, the brownfield site is expected to produce EZ-filled syringes, vials, and other products.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.2.1 Bargaining Power of Suppliers
    • 4.2.2 Bargaining Power of Buyers
    • 4.2.3 Threat of New Entrants
    • 4.2.4 Threat of Substitutes
    • 4.2.5 Intensity of Competitive Rivalry
  • 4.3 Assessment of the Impact of COVID-19 on the Industry
  • 4.4 Industry Value Chain Analysis

5 MARKET DYNAMICS

  • 5.1 Market Drivers
    • 5.1.1 Growth of the Pharmaceutical Industry in Emerging Economies
    • 5.1.2 Commodity Value of Glass Increased with Recyclability
  • 5.2 Market Restraints
    • 5.2.1 Increased Relevance of Alternate Sources

6 MARKET SEGMENTATION

  • 6.1 By Application
    • 6.1.1 Vaccines
    • 6.1.2 Others (Insulin, Biopharma, Others)
  • 6.2 By Geography
    • 6.2.1 North America
      • 6.2.1.1 United States
      • 6.2.1.2 Canada
    • 6.2.2 Europe
      • 6.2.2.1 Germany
      • 6.2.2.2 United Kingdom
      • 6.2.2.3 France
      • 6.2.2.4 Italy
      • 6.2.2.5 Spain
      • 6.2.2.6 Rest of Europe
    • 6.2.3 Asia-Pacific
      • 6.2.3.1 China
      • 6.2.3.2 Japan
      • 6.2.3.3 India
      • 6.2.3.4 South Korea
      • 6.2.3.5 Rest of Asia-Pacific
    • 6.2.4 Rest of the World

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Schott AG
    • 7.1.2 Gerresheimer AG
    • 7.1.3 Stevanato Group SPA
    • 7.1.4 NIPRO Corporation
    • 7.1.5 Kapoor Glass India Pvt. Ltd
    • 7.1.6 SGD SA (SGD Pharma)
    • 7.1.7 AAPL Solutions Pvt. Ltd
    • 7.1.8 CORNING INCORPORATED
    • 7.1.9 BOROSIL
    • 7.1.10 Stoelzle Oberglas GmbH
    • 7.1.11 Accu-Glass LLC
    • 7.1.12 Adit Containers Private Limited
    • 7.1.13 Agrado SA
    • 7.1.14 Birgimefar Group
    • 7.1.15 J. Penner Corporation
    • 7.1.16 BORMIOLI PHARMA SPA
    • 7.1.17 SISECAM

8 INVESTMENT ANALYSIS

9 FUTURE OF THE MARKET